Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will report Full Year 2021 financial and operating results on the evening of Thursday, March 24th.
Following the press release, Celyad management will host a conference call on Friday, March 25 th at 1 p.m. CET / 8 a.m. ET to discuss Full Year 2021 results and provide an update on the Company’s recent progress and upcoming milestones.
Participants may access the conference call by dialing +1-412-317-6060 (International), +1-866-652-5200 (United States) or +32 (0) 800-38913 (Belgium).
To access the live webcast and archived recording, visit the “Events” section of the Celyad website.
